Scholarlink

<p>This study introduces a novel wafer-based nanoplatform integrating quercetin (QER)-loaded, chitosan-coated oleosomes (F3) with green-synthesized Polycladia myrica-mediated zinc oxide nanoparticles (PZnONPs, 22.95–29.51&#xa0;nm) into sodium carboxymethyl cellulose (NaCMC) matrices for enhanced antiviral, anti-inflammatory, and hepatoprotective effects. Comprehensive characterization confirmed nanoscale uniformity, high QER encapsulation (96.7%), positive ζ-potential (+19.7 mV), and biphasic sustained release from F3 oleosomes (up to 120&#xa0;h), further extended to 144&#xa0;h in wafers with minimized burst. The dual-loaded F3/PZnONPs wafers exhibited superior hepatoprotection (IC50 = 23.25&#xa0;µg/mL) over free QER, improved HAV antiviral activity via nanoencapsulation synergy, and sustained COX-2 inhibition despite lower acute potency (vs. free QER IC50 = 4.67&#xa0;µg/mL), highlighting the novelty of prolonged multi-target delivery. These findings underscore the platform’s clinical translation potential, pending in vivo validation.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biophysical Characterization of Wafers Co-loading Quercetin Loaded Chitosan-Coated Oleosomes and Polycladia Myrica-Mediated Zinc Oxide Nanoparticles for Antiviral, Anti-inflammatory and Hepatoprotective Therapy

  • 期刊论文

  • 发表日期：

    2026年4月29日

查看全文
  • Mofida E. M. Makhlof,
  • Mariam Zewail,
  • Sahar E. Abo-Neima,
  • Mohammad Y. Alfaifi,
  • Ali A. Shati,
  • Fatma Alzahraa Mokhtar

摘要

This study introduces a novel wafer-based nanoplatform integrating quercetin (QER)-loaded, chitosan-coated oleosomes (F3) with green-synthesized Polycladia myrica-mediated zinc oxide nanoparticles (PZnONPs, 22.95–29.51 nm) into sodium carboxymethyl cellulose (NaCMC) matrices for enhanced antiviral, anti-inflammatory, and hepatoprotective effects. Comprehensive characterization confirmed nanoscale uniformity, high QER encapsulation (96.7%), positive ζ-potential (+19.7 mV), and biphasic sustained release from F3 oleosomes (up to 120 h), further extended to 144 h in wafers with minimized burst. The dual-loaded F3/PZnONPs wafers exhibited superior hepatoprotection (IC50 = 23.25 µg/mL) over free QER, improved HAV antiviral activity via nanoencapsulation synergy, and sustained COX-2 inhibition despite lower acute potency (vs. free QER IC50 = 4.67 µg/mL), highlighting the novelty of prolonged multi-target delivery. These findings underscore the platform’s clinical translation potential, pending in vivo validation.

Graphical Abstract